Revitalist Lifestyle and Wellness Ltd.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, FSNUY has a market cap of 109.76B. Regarding current trading prices, RVLWF is priced at $0.04, while FSNUY trades at $12.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas FSNUY's P/E ratio is 27.07. In terms of profitability, RVLWF's ROE is +3.95%, compared to FSNUY's ROE of +0.02%. Regarding short-term risk, RVLWF is less volatile compared to FSNUY. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, HCA has a market cap of 85.12B. Regarding current trading prices, RVLWF is priced at $0.04, while HCA trades at $353.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas HCA's P/E ratio is 15.70. In terms of profitability, RVLWF's ROE is +3.95%, compared to HCA's ROE of -2.36%. Regarding short-term risk, RVLWF is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, FSNUF has a market cap of 21.25B. Regarding current trading prices, RVLWF is priced at $0.04, while FSNUF trades at $37.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas FSNUF's P/E ratio is 20.85. In terms of profitability, RVLWF's ROE is +3.95%, compared to FSNUF's ROE of +0.02%. Regarding short-term risk, RVLWF is less volatile compared to FSNUF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, FMS has a market cap of 16.64B. Regarding current trading prices, RVLWF is priced at $0.04, while FMS trades at $28.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas FMS's P/E ratio is 23.83. In terms of profitability, RVLWF's ROE is +3.95%, compared to FMS's ROE of +0.04%. Regarding short-term risk, RVLWF is less volatile compared to FMS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, FMCQF has a market cap of 15.33B. Regarding current trading prices, RVLWF is priced at $0.04, while FMCQF trades at $52.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas FMCQF's P/E ratio is 21.86. In terms of profitability, RVLWF's ROE is +3.95%, compared to FMCQF's ROE of +0.04%. Regarding short-term risk, RVLWF is less volatile compared to FMCQF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, THC has a market cap of 13.82B. Regarding current trading prices, RVLWF is priced at $0.04, while THC trades at $148.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas THC's P/E ratio is 9.54. In terms of profitability, RVLWF's ROE is +3.95%, compared to THC's ROE of +0.37%. Regarding short-term risk, RVLWF is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BDUUY has a market cap of 12.84B. Regarding current trading prices, RVLWF is priced at $0.04, while BDUUY trades at $32.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BDUUY's P/E ratio is 28.36. In terms of profitability, RVLWF's ROE is +3.95%, compared to BDUUY's ROE of +0.16%. Regarding short-term risk, RVLWF is less volatile compared to BDUUY. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SOLV has a market cap of 12.16B. Regarding current trading prices, RVLWF is priced at $0.04, while SOLV trades at $70.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SOLV's P/E ratio is 25.46. In terms of profitability, RVLWF's ROE is +3.95%, compared to SOLV's ROE of +0.15%. Regarding short-term risk, RVLWF is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, UHS has a market cap of 11.85B. Regarding current trading prices, RVLWF is priced at $0.04, while UHS trades at $181.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas UHS's P/E ratio is 10.21. In terms of profitability, RVLWF's ROE is +3.95%, compared to UHS's ROE of +0.18%. Regarding short-term risk, RVLWF is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, EHC has a market cap of 11.73B. Regarding current trading prices, RVLWF is priced at $0.04, while EHC trades at $116.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas EHC's P/E ratio is 23.95. In terms of profitability, RVLWF's ROE is +3.95%, compared to EHC's ROE of +0.25%. Regarding short-term risk, RVLWF is less volatile compared to EHC. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BDULF has a market cap of 11.66B. Regarding current trading prices, RVLWF is priced at $0.04, while BDULF trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BDULF's P/E ratio is 23.67. In terms of profitability, RVLWF's ROE is +3.95%, compared to BDULF's ROE of +0.16%. Regarding short-term risk, RVLWF is less volatile compared to BDULF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, DVA has a market cap of 11.05B. Regarding current trading prices, RVLWF is priced at $0.04, while DVA trades at $143.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas DVA's P/E ratio is 13.40. In terms of profitability, RVLWF's ROE is +3.95%, compared to DVA's ROE of +1.81%. Regarding short-term risk, RVLWF is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BDUUF has a market cap of 10.49B. Regarding current trading prices, RVLWF is priced at $0.04, while BDUUF trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BDUUF's P/E ratio is 22.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to BDUUF's ROE of +0.16%. Regarding short-term risk, RVLWF is less volatile compared to BDUUF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, JDHIY has a market cap of 10.40B. Regarding current trading prices, RVLWF is priced at $0.04, while JDHIY trades at $3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas JDHIY's P/E ratio is 18.06. In terms of profitability, RVLWF's ROE is +3.95%, compared to JDHIY's ROE of +0.05%. Regarding short-term risk, RVLWF and JDHIY have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, JDHIF has a market cap of 10.33B. Regarding current trading prices, RVLWF is priced at $0.04, while JDHIF trades at $3.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas JDHIF's P/E ratio is 26.92. In terms of profitability, RVLWF's ROE is +3.95%, compared to JDHIF's ROE of +0.05%. Regarding short-term risk, RVLWF is less volatile compared to JDHIF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, IHHHF has a market cap of 9.70B. Regarding current trading prices, RVLWF is priced at $0.04, while IHHHF trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas IHHHF's P/E ratio is 15.71. In terms of profitability, RVLWF's ROE is +3.95%, compared to IHHHF's ROE of +0.09%. Regarding short-term risk, RVLWF is less volatile compared to IHHHF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, OSH has a market cap of 9.52B. Regarding current trading prices, RVLWF is priced at $0.04, while OSH trades at $39.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas OSH's P/E ratio is -17.65. In terms of profitability, RVLWF's ROE is +3.95%, compared to OSH's ROE of +4.64%. Regarding short-term risk, RVLWF is less volatile compared to OSH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CHE has a market cap of 8.35B. Regarding current trading prices, RVLWF is priced at $0.04, while CHE trades at $570.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CHE's P/E ratio is 27.85. In terms of profitability, RVLWF's ROE is +3.95%, compared to CHE's ROE of +0.26%. Regarding short-term risk, RVLWF is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ENSG has a market cap of 7.86B. Regarding current trading prices, RVLWF is priced at $0.04, while ENSG trades at $136.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ENSG's P/E ratio is 25.79. In terms of profitability, RVLWF's ROE is +3.95%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, RVLWF is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, LHCG has a market cap of 5.29B. Regarding current trading prices, RVLWF is priced at $0.04, while LHCG trades at $169.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas LHCG's P/E ratio is 82.83. In terms of profitability, RVLWF's ROE is +3.95%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, RVLWF is less volatile compared to LHCG. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, OPCH has a market cap of 5.21B. Regarding current trading prices, RVLWF is priced at $0.04, while OPCH trades at $31.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas OPCH's P/E ratio is 25.47. In terms of profitability, RVLWF's ROE is +3.95%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, RVLWF is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RMSYF has a market cap of 5.06B. Regarding current trading prices, RVLWF is priced at $0.04, while RMSYF trades at $22.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RMSYF's P/E ratio is 440.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to RMSYF's ROE of +0.18%. Regarding short-term risk, RVLWF is less volatile compared to RMSYF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BUGDF has a market cap of 5.02B. Regarding current trading prices, RVLWF is priced at $0.04, while BUGDF trades at $6.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BUGDF's P/E ratio is 24.27. In terms of profitability, RVLWF's ROE is +3.95%, compared to BUGDF's ROE of +0.28%. Regarding short-term risk, RVLWF is less volatile compared to BUGDF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RMYHY has a market cap of 5.00B. Regarding current trading prices, RVLWF is priced at $0.04, while RMYHY trades at $5.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RMYHY's P/E ratio is 513.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to RMYHY's ROE of +0.18%. Regarding short-term risk, RVLWF is less volatile compared to RMYHY. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ANHGY has a market cap of 4.05B. Regarding current trading prices, RVLWF is priced at $0.04, while ANHGY trades at $5.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, RVLWF's ROE is +3.95%, compared to ANHGY's ROE of N/A. Regarding short-term risk, RVLWF and ANHGY have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BUHPF has a market cap of 3.86B. Regarding current trading prices, RVLWF is priced at $0.04, while BUHPF trades at $4.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BUHPF's P/E ratio is 18.65. In terms of profitability, RVLWF's ROE is +3.95%, compared to BUHPF's ROE of +0.28%. Regarding short-term risk, RVLWF is less volatile compared to BUHPF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AMED has a market cap of 3.13B. Regarding current trading prices, RVLWF is priced at $0.04, while AMED trades at $95.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AMED's P/E ratio is 35.17. In terms of profitability, RVLWF's ROE is +3.95%, compared to AMED's ROE of +0.10%. Regarding short-term risk, RVLWF is less volatile compared to AMED. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SGRY has a market cap of 3.05B. Regarding current trading prices, RVLWF is priced at $0.04, while SGRY trades at $23.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SGRY's P/E ratio is -18.02. In terms of profitability, RVLWF's ROE is +3.95%, compared to SGRY's ROE of -0.09%. Regarding short-term risk, RVLWF is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MCVEF has a market cap of 2.98B. Regarding current trading prices, RVLWF is priced at $0.04, while MCVEF trades at $19.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MCVEF's P/E ratio is 86.22. In terms of profitability, RVLWF's ROE is +3.95%, compared to MCVEF's ROE of +0.06%. Regarding short-term risk, RVLWF is less volatile compared to MCVEF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ORPEF has a market cap of 2.29B. Regarding current trading prices, RVLWF is priced at $0.04, while ORPEF trades at $14.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ORPEF's P/E ratio is 0.03. In terms of profitability, RVLWF's ROE is +3.95%, compared to ORPEF's ROE of +0.91%. Regarding short-term risk, RVLWF is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, LFST has a market cap of 2.23B. Regarding current trading prices, RVLWF is priced at $0.04, while LFST trades at $5.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas LFST's P/E ratio is -63.67. In terms of profitability, RVLWF's ROE is +3.95%, compared to LFST's ROE of -0.04%. Regarding short-term risk, RVLWF is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ACHC has a market cap of 2.20B. Regarding current trading prices, RVLWF is priced at $0.04, while ACHC trades at $23.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ACHC's P/E ratio is 8.58. In terms of profitability, RVLWF's ROE is +3.95%, compared to ACHC's ROE of +0.09%. Regarding short-term risk, RVLWF is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MCVEY has a market cap of 2.16B. Regarding current trading prices, RVLWF is priced at $0.04, while MCVEY trades at $16.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MCVEY's P/E ratio is 40.37. In terms of profitability, RVLWF's ROE is +3.95%, compared to MCVEY's ROE of N/A. Regarding short-term risk, RVLWF is less volatile compared to MCVEY. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ARDT has a market cap of 2.08B. Regarding current trading prices, RVLWF is priced at $0.04, while ARDT trades at $14.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ARDT's P/E ratio is 8.65. In terms of profitability, RVLWF's ROE is +3.95%, compared to ARDT's ROE of +0.30%. Regarding short-term risk, RVLWF is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ADUS has a market cap of 2.04B. Regarding current trading prices, RVLWF is priced at $0.04, while ADUS trades at $110.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ADUS's P/E ratio is 25.09. In terms of profitability, RVLWF's ROE is +3.95%, compared to ADUS's ROE of +0.08%. Regarding short-term risk, RVLWF is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SEM has a market cap of 1.92B. Regarding current trading prices, RVLWF is priced at $0.04, while SEM trades at $14.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SEM's P/E ratio is 24.04. In terms of profitability, RVLWF's ROE is +3.95%, compared to SEM's ROE of +0.10%. Regarding short-term risk, RVLWF is less volatile compared to SEM. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AMEH has a market cap of 1.83B. Regarding current trading prices, RVLWF is priced at $0.04, while AMEH trades at $40.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AMEH's P/E ratio is 39.25. In terms of profitability, RVLWF's ROE is +3.95%, compared to AMEH's ROE of +0.06%. Regarding short-term risk, RVLWF is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ASTH has a market cap of 1.67B. Regarding current trading prices, RVLWF is priced at $0.04, while ASTH trades at $29.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ASTH's P/E ratio is 33.01. In terms of profitability, RVLWF's ROE is +3.95%, compared to ASTH's ROE of +0.06%. Regarding short-term risk, RVLWF is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TTALF has a market cap of 1.64B. Regarding current trading prices, RVLWF is priced at $0.04, while TTALF trades at $12.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TTALF's P/E ratio is 19.33. In terms of profitability, RVLWF's ROE is +3.95%, compared to TTALF's ROE of +0.15%. Regarding short-term risk, RVLWF and TTALF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BKD has a market cap of 1.60B. Regarding current trading prices, RVLWF is priced at $0.04, while BKD trades at $6.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BKD's P/E ratio is -6.58. In terms of profitability, RVLWF's ROE is +3.95%, compared to BKD's ROE of -0.66%. Regarding short-term risk, RVLWF is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NHC has a market cap of 1.55B. Regarding current trading prices, RVLWF is priced at $0.04, while NHC trades at $100.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NHC's P/E ratio is 15.40. In terms of profitability, RVLWF's ROE is +3.95%, compared to NHC's ROE of +0.11%. Regarding short-term risk, RVLWF is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RYHTY has a market cap of 1.54B. Regarding current trading prices, RVLWF is priced at $0.04, while RYHTY trades at $7.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RYHTY's P/E ratio is -21.06. In terms of profitability, RVLWF's ROE is +3.95%, compared to RYHTY's ROE of +0.00%. Regarding short-term risk, RVLWF and RYHTY have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RHCGF has a market cap of 1.43B. Regarding current trading prices, RVLWF is priced at $0.04, while RHCGF trades at $1.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RHCGF's P/E ratio is -20.14. In terms of profitability, RVLWF's ROE is +3.95%, compared to RHCGF's ROE of -0.02%. Regarding short-term risk, RVLWF is less volatile compared to RHCGF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MD has a market cap of 1.25B. Regarding current trading prices, RVLWF is priced at $0.04, while MD trades at $14.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MD's P/E ratio is -14.52. In terms of profitability, RVLWF's ROE is +3.95%, compared to MD's ROE of -0.13%. Regarding short-term risk, RVLWF is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BKDT has a market cap of 1.23B. Regarding current trading prices, RVLWF is priced at $0.04, while BKDT trades at $77.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BKDT's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to BKDT's ROE of -0.66%. Regarding short-term risk, RVLWF is less volatile compared to BKDT. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AGL has a market cap of 1.19B. Regarding current trading prices, RVLWF is priced at $0.04, while AGL trades at $2.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AGL's P/E ratio is -4.62. In terms of profitability, RVLWF's ROE is +3.95%, compared to AGL's ROE of -0.42%. Regarding short-term risk, RVLWF is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, LTGHF has a market cap of 1.18B. Regarding current trading prices, RVLWF is priced at $0.04, while LTGHF trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas LTGHF's P/E ratio is 11.70. In terms of profitability, RVLWF's ROE is +3.95%, compared to LTGHF's ROE of +0.29%. Regarding short-term risk, RVLWF is less volatile compared to LTGHF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, LWSCF has a market cap of 1.15B. Regarding current trading prices, RVLWF is priced at $0.04, while LWSCF trades at $12.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas LWSCF's P/E ratio is 41.52. In terms of profitability, RVLWF's ROE is +3.95%, compared to LWSCF's ROE of +0.09%. Regarding short-term risk, RVLWF is less volatile compared to LWSCF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, LTGHY has a market cap of 1.13B. Regarding current trading prices, RVLWF is priced at $0.04, while LTGHY trades at $3.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas LTGHY's P/E ratio is 10.33. In terms of profitability, RVLWF's ROE is +3.95%, compared to LTGHY's ROE of +0.40%. Regarding short-term risk, RVLWF is less volatile compared to LTGHY. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, USPH has a market cap of 1.13B. Regarding current trading prices, RVLWF is priced at $0.04, while USPH trades at $74.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas USPH's P/E ratio is 40.27. In terms of profitability, RVLWF's ROE is +3.95%, compared to USPH's ROE of +0.05%. Regarding short-term risk, RVLWF is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RAFLF has a market cap of 1.11B. Regarding current trading prices, RVLWF is priced at $0.04, while RAFLF trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RAFLF's P/E ratio is 20.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to RAFLF's ROE of +0.04%. Regarding short-term risk, RVLWF is less volatile compared to RAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AVAH has a market cap of 1.05B. Regarding current trading prices, RVLWF is priced at $0.04, while AVAH trades at $5.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AVAH's P/E ratio is -90.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to AVAH's ROE of +0.08%. Regarding short-term risk, RVLWF is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RKAGY has a market cap of 1.05B. Regarding current trading prices, RVLWF is priced at $0.04, while RKAGY trades at $7.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RKAGY's P/E ratio is 21.22. In terms of profitability, RVLWF's ROE is +3.95%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, RVLWF is less volatile compared to RKAGY. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, HCSG has a market cap of 1.04B. Regarding current trading prices, RVLWF is priced at $0.04, while HCSG trades at $14.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas HCSG's P/E ratio is 25.95. In terms of profitability, RVLWF's ROE is +3.95%, compared to HCSG's ROE of +0.08%. Regarding short-term risk, RVLWF is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RHKJF has a market cap of 1.02B. Regarding current trading prices, RVLWF is priced at $0.04, while RHKJF trades at $15.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, RVLWF's ROE is +3.95%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, RVLWF is less volatile compared to RHKJF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, PNTG has a market cap of 985.12M. Regarding current trading prices, RVLWF is priced at $0.04, while PNTG trades at $28.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas PNTG's P/E ratio is 40.83. In terms of profitability, RVLWF's ROE is +3.95%, compared to PNTG's ROE of +0.12%. Regarding short-term risk, RVLWF is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NWKHY has a market cap of 945.10M. Regarding current trading prices, RVLWF is priced at $0.04, while NWKHY trades at $7.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NWKHY's P/E ratio is 13.22. In terms of profitability, RVLWF's ROE is +3.95%, compared to NWKHY's ROE of +0.13%. Regarding short-term risk, RVLWF is less volatile compared to NWKHY. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, EXETF has a market cap of 857.21M. Regarding current trading prices, RVLWF is priced at $0.04, while EXETF trades at $10.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas EXETF's P/E ratio is 16.05. In terms of profitability, RVLWF's ROE is +3.95%, compared to EXETF's ROE of +0.69%. Regarding short-term risk, RVLWF and EXETF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AMN has a market cap of 840.61M. Regarding current trading prices, RVLWF is priced at $0.04, while AMN trades at $22.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AMN's P/E ratio is -5.72. In terms of profitability, RVLWF's ROE is +3.95%, compared to AMN's ROE of -0.18%. Regarding short-term risk, RVLWF is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, JXFGF has a market cap of 755.56M. Regarding current trading prices, RVLWF is priced at $0.04, while JXFGF trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas JXFGF's P/E ratio is 14.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to JXFGF's ROE of +0.03%. Regarding short-term risk, RVLWF is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, WHTCF has a market cap of 708.39M. Regarding current trading prices, RVLWF is priced at $0.04, while WHTCF trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas WHTCF's P/E ratio is 31.12. In terms of profitability, RVLWF's ROE is +3.95%, compared to WHTCF's ROE of +0.04%. Regarding short-term risk, RVLWF is less volatile compared to WHTCF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, KDGTF has a market cap of 675.13M. Regarding current trading prices, RVLWF is priced at $0.04, while KDGTF trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, RVLWF's ROE is +3.95%, compared to KDGTF's ROE of N/A. Regarding short-term risk, RVLWF and KDGTF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, EHAB has a market cap of 519.54M. Regarding current trading prices, RVLWF is priced at $0.04, while EHAB trades at $10.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas EHAB's P/E ratio is -3.30. In terms of profitability, RVLWF's ROE is +3.95%, compared to EHAB's ROE of -0.26%. Regarding short-term risk, RVLWF is less volatile compared to EHAB. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AUNA has a market cap of 506.25M. Regarding current trading prices, RVLWF is priced at $0.04, while AUNA trades at $6.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AUNA's P/E ratio is 15.55. In terms of profitability, RVLWF's ROE is +3.95%, compared to AUNA's ROE of +0.07%. Regarding short-term risk, RVLWF is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TALK has a market cap of 505.45M. Regarding current trading prices, RVLWF is priced at $0.04, while TALK trades at $3.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TALK's P/E ratio is 302.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to TALK's ROE of -0.04%. Regarding short-term risk, RVLWF is less volatile compared to TALK. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TALKW has a market cap of 496.39M. Regarding current trading prices, RVLWF is priced at $0.04, while TALKW trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TALKW's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to TALKW's ROE of -0.04%. Regarding short-term risk, RVLWF and TALKW have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, INNV has a market cap of 491.45M. Regarding current trading prices, RVLWF is priced at $0.04, while INNV trades at $3.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas INNV's P/E ratio is -19.16. In terms of profitability, RVLWF's ROE is +3.95%, compared to INNV's ROE of -0.10%. Regarding short-term risk, RVLWF is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CYH has a market cap of 491.07M. Regarding current trading prices, RVLWF is priced at $0.04, while CYH trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CYH's P/E ratio is -0.95. In terms of profitability, RVLWF's ROE is +3.95%, compared to CYH's ROE of +0.30%. Regarding short-term risk, RVLWF is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, WFHG has a market cap of 470.60M. Regarding current trading prices, RVLWF is priced at $0.04, while WFHG trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas WFHG's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to WFHG's ROE of +0.22%. Regarding short-term risk, RVLWF is less volatile compared to WFHG. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SNDA has a market cap of 468.24M. Regarding current trading prices, RVLWF is priced at $0.04, while SNDA trades at $24.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SNDA's P/E ratio is -45.96. In terms of profitability, RVLWF's ROE is +3.95%, compared to SNDA's ROE of -0.03%. Regarding short-term risk, RVLWF is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CCRN has a market cap of 459.29M. Regarding current trading prices, RVLWF is priced at $0.04, while CCRN trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CCRN's P/E ratio is -31.84. In terms of profitability, RVLWF's ROE is +3.95%, compared to CCRN's ROE of -0.03%. Regarding short-term risk, RVLWF is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ORRRY has a market cap of 371.54M. Regarding current trading prices, RVLWF is priced at $0.04, while ORRRY trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, RVLWF's ROE is +3.95%, compared to ORRRY's ROE of +73.42%. Regarding short-term risk, RVLWF and ORRRY have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BTMDW has a market cap of 292.88M. Regarding current trading prices, RVLWF is priced at $0.04, while BTMDW trades at $1.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, RVLWF's ROE is +3.95%, compared to BTMDW's ROE of -0.06%. Regarding short-term risk, RVLWF is less volatile compared to BTMDW. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CMPS has a market cap of 259.81M. Regarding current trading prices, RVLWF is priced at $0.04, while CMPS trades at $3.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CMPS's P/E ratio is -1.65. In terms of profitability, RVLWF's ROE is +3.95%, compared to CMPS's ROE of -0.74%. Regarding short-term risk, RVLWF is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MFCSF has a market cap of 252.17M. Regarding current trading prices, RVLWF is priced at $0.04, while MFCSF trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MFCSF's P/E ratio is 8.09. In terms of profitability, RVLWF's ROE is +3.95%, compared to MFCSF's ROE of +0.83%. Regarding short-term risk, RVLWF is less volatile compared to MFCSF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, EVGRF has a market cap of 237.47M. Regarding current trading prices, RVLWF is priced at $0.04, while EVGRF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas EVGRF's P/E ratio is -0.05. In terms of profitability, RVLWF's ROE is +3.95%, compared to EVGRF's ROE of +0.67%. Regarding short-term risk, RVLWF is less volatile compared to EVGRF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MKLNF has a market cap of 224.32M. Regarding current trading prices, RVLWF is priced at $0.04, while MKLNF trades at $11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, RVLWF's ROE is +3.95%, compared to MKLNF's ROE of +0.15%. Regarding short-term risk, RVLWF and MKLNF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CSU has a market cap of 223.71M. Regarding current trading prices, RVLWF is priced at $0.04, while CSU trades at $33.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CSU's P/E ratio is 0.67. In terms of profitability, RVLWF's ROE is +3.95%, compared to CSU's ROE of +2.23%. Regarding short-term risk, RVLWF is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BTMD has a market cap of 218.84M. Regarding current trading prices, RVLWF is priced at $0.04, while BTMD trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BTMD's P/E ratio is 44.44. In terms of profitability, RVLWF's ROE is +3.95%, compared to BTMD's ROE of -0.06%. Regarding short-term risk, RVLWF is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TOI has a market cap of 212.11M. Regarding current trading prices, RVLWF is priced at $0.04, while TOI trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TOI's P/E ratio is -3.94. In terms of profitability, RVLWF's ROE is +3.95%, compared to TOI's ROE of -2.73%. Regarding short-term risk, RVLWF is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AIRS has a market cap of 175.75M. Regarding current trading prices, RVLWF is priced at $0.04, while AIRS trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AIRS's P/E ratio is -10.31. In terms of profitability, RVLWF's ROE is +3.95%, compared to AIRS's ROE of -0.21%. Regarding short-term risk, RVLWF is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AONC has a market cap of 171.11M. Regarding current trading prices, RVLWF is priced at $0.04, while AONC trades at $5.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AONC's P/E ratio is -6.57. In terms of profitability, RVLWF's ROE is +3.95%, compared to AONC's ROE of +0.25%. Regarding short-term risk, RVLWF is less volatile compared to AONC. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, JYNT has a market cap of 153.07M. Regarding current trading prices, RVLWF is priced at $0.04, while JYNT trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas JYNT's P/E ratio is -99.90. In terms of profitability, RVLWF's ROE is +3.95%, compared to JYNT's ROE of -0.00%. Regarding short-term risk, RVLWF is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, DCGO has a market cap of 139.92M. Regarding current trading prices, RVLWF is priced at $0.04, while DCGO trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas DCGO's P/E ratio is 7.78. In terms of profitability, RVLWF's ROE is +3.95%, compared to DCGO's ROE of +0.00%. Regarding short-term risk, RVLWF is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CHHHF has a market cap of 121.49M. Regarding current trading prices, RVLWF is priced at $0.04, while CHHHF trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CHHHF's P/E ratio is -39.20. In terms of profitability, RVLWF's ROE is +3.95%, compared to CHHHF's ROE of -0.06%. Regarding short-term risk, RVLWF and CHHHF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, VTIAF has a market cap of 104.42M. Regarding current trading prices, RVLWF is priced at $0.04, while VTIAF trades at $5.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas VTIAF's P/E ratio is -3.59. In terms of profitability, RVLWF's ROE is +3.95%, compared to VTIAF's ROE of +0.11%. Regarding short-term risk, RVLWF is less volatile compared to VTIAF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, FVE has a market cap of 98.39M. Regarding current trading prices, RVLWF is priced at $0.04, while FVE trades at $2.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas FVE's P/E ratio is -5.64. In terms of profitability, RVLWF's ROE is +3.95%, compared to FVE's ROE of -0.15%. Regarding short-term risk, RVLWF is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, PIII has a market cap of 62.56M. Regarding current trading prices, RVLWF is priced at $0.04, while PIII trades at $8.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas PIII's P/E ratio is -0.16. In terms of profitability, RVLWF's ROE is +3.95%, compared to PIII's ROE of -1.07%. Regarding short-term risk, RVLWF is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, PIIIW has a market cap of 58.41M. Regarding current trading prices, RVLWF is priced at $0.04, while PIIIW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, RVLWF's ROE is +3.95%, compared to PIIIW's ROE of -1.07%. Regarding short-term risk, RVLWF and PIIIW have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MCIOF has a market cap of 54.04M. Regarding current trading prices, RVLWF is priced at $0.04, while MCIOF trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, RVLWF's ROE is +3.95%, compared to MCIOF's ROE of N/A. Regarding short-term risk, RVLWF and MCIOF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ASSF has a market cap of 45.35M. Regarding current trading prices, RVLWF is priced at $0.04, while ASSF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ASSF's P/E ratio is -33.33. In terms of profitability, RVLWF's ROE is +3.95%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, RVLWF and ASSF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, KONEF has a market cap of 44.34M. Regarding current trading prices, RVLWF is priced at $0.04, while KONEF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas KONEF's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, RVLWF is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ALR has a market cap of 44.18M. Regarding current trading prices, RVLWF is priced at $0.04, while ALR trades at $1.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ALR's P/E ratio is -1.11. In terms of profitability, RVLWF's ROE is +3.95%, compared to ALR's ROE of -0.15%. Regarding short-term risk, RVLWF is less volatile compared to ALR. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CCEL has a market cap of 40.77M. Regarding current trading prices, RVLWF is priced at $0.04, while CCEL trades at $5.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CCEL's P/E ratio is 504.50. In terms of profitability, RVLWF's ROE is +3.95%, compared to CCEL's ROE of -0.01%. Regarding short-term risk, RVLWF is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, IMAC has a market cap of 33.08M. Regarding current trading prices, RVLWF is priced at $0.04, while IMAC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas IMAC's P/E ratio is -2.27. In terms of profitability, RVLWF's ROE is +3.95%, compared to IMAC's ROE of +2.46%. Regarding short-term risk, RVLWF is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, HQDA has a market cap of 18.64M. Regarding current trading prices, RVLWF is priced at $0.04, while HQDA trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas HQDA's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to HQDA's ROE of +0.00%. Regarding short-term risk, RVLWF and HQDA have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AMS has a market cap of 18.06M. Regarding current trading prices, RVLWF is priced at $0.04, while AMS trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AMS's P/E ratio is 8.48. In terms of profitability, RVLWF's ROE is +3.95%, compared to AMS's ROE of +0.09%. Regarding short-term risk, RVLWF is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MODV has a market cap of 16.79M. Regarding current trading prices, RVLWF is priced at $0.04, while MODV trades at $1.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MODV's P/E ratio is -0.08. In terms of profitability, RVLWF's ROE is +3.95%, compared to MODV's ROE of -8.96%. Regarding short-term risk, RVLWF is less volatile compared to MODV. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NVLPF has a market cap of 16.59M. Regarding current trading prices, RVLWF is priced at $0.04, while NVLPF trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NVLPF's P/E ratio is 9.50. In terms of profitability, RVLWF's ROE is +3.95%, compared to NVLPF's ROE of +0.08%. Regarding short-term risk, RVLWF and NVLPF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AIH has a market cap of 15.93M. Regarding current trading prices, RVLWF is priced at $0.04, while AIH trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AIH's P/E ratio is -2.78. In terms of profitability, RVLWF's ROE is +3.95%, compared to AIH's ROE of -0.79%. Regarding short-term risk, RVLWF is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, USNU has a market cap of 14.77M. Regarding current trading prices, RVLWF is priced at $0.04, while USNU trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas USNU's P/E ratio is -5.31. In terms of profitability, RVLWF's ROE is +3.95%, compared to USNU's ROE of -0.81%. Regarding short-term risk, RVLWF is less volatile compared to USNU. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CANO has a market cap of 12.43M. Regarding current trading prices, RVLWF is priced at $0.04, while CANO trades at $2.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CANO's P/E ratio is -0.01. In terms of profitability, RVLWF's ROE is +3.95%, compared to CANO's ROE of -32.61%. Regarding short-term risk, RVLWF is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, FPCG has a market cap of 10.25M. Regarding current trading prices, RVLWF is priced at $0.04, while FPCG trades at $1,025.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas FPCG's P/E ratio is 0.09. In terms of profitability, RVLWF's ROE is +3.95%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, RVLWF and FPCG have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, FTRP has a market cap of 9.81M. Regarding current trading prices, RVLWF is priced at $0.04, while FTRP trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas FTRP's P/E ratio is -1.22. In terms of profitability, RVLWF's ROE is +3.95%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, RVLWF is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NUMIF has a market cap of 8.23M. Regarding current trading prices, RVLWF is priced at $0.04, while NUMIF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NUMIF's P/E ratio is -0.42. In terms of profitability, RVLWF's ROE is +3.95%, compared to NUMIF's ROE of -1.95%. Regarding short-term risk, RVLWF is less volatile compared to NUMIF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, XCRT has a market cap of 7.95M. Regarding current trading prices, RVLWF is priced at $0.04, while XCRT trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas XCRT's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to XCRT's ROE of +2.48%. Regarding short-term risk, RVLWF is less volatile compared to XCRT. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, HLYK has a market cap of 6.62M. Regarding current trading prices, RVLWF is priced at $0.04, while HLYK trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas HLYK's P/E ratio is -1.17. In terms of profitability, RVLWF's ROE is +3.95%, compared to HLYK's ROE of +4.66%. Regarding short-term risk, RVLWF is less volatile compared to HLYK. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, GBCS has a market cap of 6.13M. Regarding current trading prices, RVLWF is priced at $0.04, while GBCS trades at $2.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas GBCS's P/E ratio is -2.50. In terms of profitability, RVLWF's ROE is +3.95%, compared to GBCS's ROE of +0.56%. Regarding short-term risk, RVLWF and GBCS have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MNDR has a market cap of 6.00M. Regarding current trading prices, RVLWF is priced at $0.04, while MNDR trades at $1.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MNDR's P/E ratio is -0.31. In terms of profitability, RVLWF's ROE is +3.95%, compared to MNDR's ROE of -5.70%. Regarding short-term risk, RVLWF is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, GBNH has a market cap of 5.52M. Regarding current trading prices, RVLWF is priced at $0.04, while GBNH trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas GBNH's P/E ratio is -0.06. In terms of profitability, RVLWF's ROE is +3.95%, compared to GBNH's ROE of +0.51%. Regarding short-term risk, RVLWF is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, VLXC has a market cap of 5.40M. Regarding current trading prices, RVLWF is priced at $0.04, while VLXC trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas VLXC's P/E ratio is -7.55. In terms of profitability, RVLWF's ROE is +3.95%, compared to VLXC's ROE of +0.68%. Regarding short-term risk, RVLWF is less volatile compared to VLXC. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RHE has a market cap of 5.21M. Regarding current trading prices, RVLWF is priced at $0.04, while RHE trades at $2.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RHE's P/E ratio is -1.79. In terms of profitability, RVLWF's ROE is +3.95%, compared to RHE's ROE of +2.66%. Regarding short-term risk, RVLWF is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TOIIW has a market cap of 4.98M. Regarding current trading prices, RVLWF is priced at $0.04, while TOIIW trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TOIIW's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to TOIIW's ROE of -2.73%. Regarding short-term risk, RVLWF is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RHEP has a market cap of 4.94M. Regarding current trading prices, RVLWF is priced at $0.04, while RHEP trades at $2.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RHEP's P/E ratio is -1.34. In terms of profitability, RVLWF's ROE is +3.95%, compared to RHEP's ROE of N/A. Regarding short-term risk, RVLWF is less volatile compared to RHEP. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BICX has a market cap of 4.62M. Regarding current trading prices, RVLWF is priced at $0.04, while BICX trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BICX's P/E ratio is -0.59. In terms of profitability, RVLWF's ROE is +3.95%, compared to BICX's ROE of +0.45%. Regarding short-term risk, RVLWF is less volatile compared to BICX. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ATIP has a market cap of 3.71M. Regarding current trading prices, RVLWF is priced at $0.04, while ATIP trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ATIP's P/E ratio is -0.04. In terms of profitability, RVLWF's ROE is +3.95%, compared to ATIP's ROE of +1.77%. Regarding short-term risk, RVLWF and ATIP have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, KDLYW has a market cap of 2.78M. Regarding current trading prices, RVLWF is priced at $0.04, while KDLYW trades at $0.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas KDLYW's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to KDLYW's ROE of -1.44%. Regarding short-term risk, RVLWF is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, EPWCF has a market cap of 2.54M. Regarding current trading prices, RVLWF is priced at $0.04, while EPWCF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas EPWCF's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, RVLWF is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, GRST has a market cap of 2.32M. Regarding current trading prices, RVLWF is priced at $0.04, while GRST trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas GRST's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to GRST's ROE of +0.30%. Regarding short-term risk, RVLWF and GRST have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, JRSS has a market cap of 1.95M. Regarding current trading prices, RVLWF is priced at $0.04, while JRSS trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas JRSS's P/E ratio is -0.38. In terms of profitability, RVLWF's ROE is +3.95%, compared to JRSS's ROE of +2.63%. Regarding short-term risk, RVLWF is less volatile compared to JRSS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TOKIF has a market cap of 1.78M. Regarding current trading prices, RVLWF is priced at $0.04, while TOKIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TOKIF's P/E ratio is -0.01. In terms of profitability, RVLWF's ROE is +3.95%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, RVLWF is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, IMACW has a market cap of 1.74M. Regarding current trading prices, RVLWF is priced at $0.04, while IMACW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas IMACW's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to IMACW's ROE of +2.46%. Regarding short-term risk, RVLWF is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SMAS has a market cap of 1.46M. Regarding current trading prices, RVLWF is priced at $0.04, while SMAS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SMAS's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to SMAS's ROE of N/A. Regarding short-term risk, RVLWF is less volatile compared to SMAS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MDGP has a market cap of 1.45M. Regarding current trading prices, RVLWF is priced at $0.04, while MDGP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MDGP's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to MDGP's ROE of N/A. Regarding short-term risk, RVLWF and MDGP have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NOVC has a market cap of 1.16M. Regarding current trading prices, RVLWF is priced at $0.04, while NOVC trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NOVC's P/E ratio is -0.20. In terms of profitability, RVLWF's ROE is +3.95%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, RVLWF and NOVC have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, PHMB has a market cap of 1.08M. Regarding current trading prices, RVLWF is priced at $0.04, while PHMB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas PHMB's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to PHMB's ROE of N/A. Regarding short-term risk, RVLWF is less volatile compared to PHMB. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CCM has a market cap of 1.07M. Regarding current trading prices, RVLWF is priced at $0.04, while CCM trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CCM's P/E ratio is -0.76. In terms of profitability, RVLWF's ROE is +3.95%, compared to CCM's ROE of +0.13%. Regarding short-term risk, RVLWF is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SYRA has a market cap of 952999.00. Regarding current trading prices, RVLWF is priced at $0.04, while SYRA trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SYRA's P/E ratio is -0.16. In terms of profitability, RVLWF's ROE is +3.95%, compared to SYRA's ROE of -1.28%. Regarding short-term risk, RVLWF is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, GNOW has a market cap of 859731.00. Regarding current trading prices, RVLWF is priced at $0.04, while GNOW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas GNOW's P/E ratio is -0.01. In terms of profitability, RVLWF's ROE is +3.95%, compared to GNOW's ROE of +0.00%. Regarding short-term risk, RVLWF and GNOW have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, RHE-PA has a market cap of 674535.00. Regarding current trading prices, RVLWF is priced at $0.04, while RHE-PA trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, RVLWF's ROE is +3.95%, compared to RHE-PA's ROE of +2.66%. Regarding short-term risk, RVLWF is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, DPAT has a market cap of 397353.00. Regarding current trading prices, RVLWF is priced at $0.04, while DPAT trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas DPAT's P/E ratio is -1.65. In terms of profitability, RVLWF's ROE is +3.95%, compared to DPAT's ROE of +0.45%. Regarding short-term risk, RVLWF and DPAT have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ARPC has a market cap of 336555.00. Regarding current trading prices, RVLWF is priced at $0.04, while ARPC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ARPC's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to ARPC's ROE of -0.56%. Regarding short-term risk, RVLWF is less volatile compared to ARPC. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NXGT has a market cap of 332870.00. Regarding current trading prices, RVLWF is priced at $0.04, while NXGT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NXGT's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to NXGT's ROE of +0.09%. Regarding short-term risk, RVLWF is less volatile compared to NXGT. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, KJFI has a market cap of 278854.00. Regarding current trading prices, RVLWF is priced at $0.04, while KJFI trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas KJFI's P/E ratio is -0.06. In terms of profitability, RVLWF's ROE is +3.95%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, RVLWF and KJFI have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, FCHS has a market cap of 263666.00. Regarding current trading prices, RVLWF is priced at $0.04, while FCHS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas FCHS's P/E ratio is -0.07. In terms of profitability, RVLWF's ROE is +3.95%, compared to FCHS's ROE of +0.12%. Regarding short-term risk, RVLWF is less volatile compared to FCHS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, JNHMF has a market cap of 165397.00. Regarding current trading prices, RVLWF is priced at $0.04, while JNHMF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas JNHMF's P/E ratio is -0.07. In terms of profitability, RVLWF's ROE is +3.95%, compared to JNHMF's ROE of +0.81%. Regarding short-term risk, RVLWF is less volatile compared to JNHMF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, HSMD has a market cap of 153388.00. Regarding current trading prices, RVLWF is priced at $0.04, while HSMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas HSMD's P/E ratio is -0.05. In terms of profitability, RVLWF's ROE is +3.95%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, RVLWF and HSMD have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SETO has a market cap of 150935.00. Regarding current trading prices, RVLWF is priced at $0.04, while SETO trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SETO's P/E ratio is -1.21. In terms of profitability, RVLWF's ROE is +3.95%, compared to SETO's ROE of +0.00%. Regarding short-term risk, RVLWF and SETO have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BNYN has a market cap of 150549.00. Regarding current trading prices, RVLWF is priced at $0.04, while BNYN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BNYN's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, RVLWF is less volatile compared to BNYN. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BACK has a market cap of 119605.00. Regarding current trading prices, RVLWF is priced at $0.04, while BACK trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BACK's P/E ratio is -0.01. In terms of profitability, RVLWF's ROE is +3.95%, compared to BACK's ROE of +2.46%. Regarding short-term risk, RVLWF and BACK have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TPIA has a market cap of 113827.00. Regarding current trading prices, RVLWF is priced at $0.04, while TPIA trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TPIA's P/E ratio is -0.15. In terms of profitability, RVLWF's ROE is +3.95%, compared to TPIA's ROE of +0.61%. Regarding short-term risk, RVLWF is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, COLRF has a market cap of 108333.00. Regarding current trading prices, RVLWF is priced at $0.04, while COLRF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas COLRF's P/E ratio is -0.01. In terms of profitability, RVLWF's ROE is +3.95%, compared to COLRF's ROE of +0.02%. Regarding short-term risk, RVLWF and COLRF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, AMBD has a market cap of 85625.00. Regarding current trading prices, RVLWF is priced at $0.04, while AMBD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas AMBD's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to AMBD's ROE of N/A. Regarding short-term risk, RVLWF is less volatile compared to AMBD. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NMHLY has a market cap of 41741.00. Regarding current trading prices, RVLWF is priced at $0.04, while NMHLY trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, RVLWF's ROE is +3.95%, compared to NMHLY's ROE of N/A. Regarding short-term risk, RVLWF and NMHLY have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, GENN has a market cap of 32696.00. Regarding current trading prices, RVLWF is priced at $0.04, while GENN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas GENN's P/E ratio is -0.02. In terms of profitability, RVLWF's ROE is +3.95%, compared to GENN's ROE of +0.00%. Regarding short-term risk, RVLWF and GENN have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, DRWN has a market cap of 23978.00. Regarding current trading prices, RVLWF is priced at $0.04, while DRWN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas DRWN's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, RVLWF is less volatile compared to DRWN. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NVOS has a market cap of 23676.00. Regarding current trading prices, RVLWF is priced at $0.04, while NVOS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NVOS's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to NVOS's ROE of -1.20%. Regarding short-term risk, RVLWF is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CLRD has a market cap of 21647.00. Regarding current trading prices, RVLWF is priced at $0.04, while CLRD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CLRD's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, RVLWF is less volatile compared to CLRD. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SCAL has a market cap of 17424.00. Regarding current trading prices, RVLWF is priced at $0.04, while SCAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SCAL's P/E ratio is 0.04. In terms of profitability, RVLWF's ROE is +3.95%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, RVLWF and SCAL have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CHCR has a market cap of 11991.00. Regarding current trading prices, RVLWF is priced at $0.04, while CHCR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CHCR's P/E ratio is -0.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to CHCR's ROE of N/A. Regarding short-term risk, RVLWF and CHCR have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ACGI has a market cap of 10477.00. Regarding current trading prices, RVLWF is priced at $0.04, while ACGI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ACGI's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, RVLWF is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, CEVE has a market cap of 7709.00. Regarding current trading prices, RVLWF is priced at $0.04, while CEVE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas CEVE's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to CEVE's ROE of N/A. Regarding short-term risk, RVLWF and CEVE have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NAFS has a market cap of 7007.00. Regarding current trading prices, RVLWF is priced at $0.04, while NAFS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NAFS's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to NAFS's ROE of +1.02%. Regarding short-term risk, RVLWF and NAFS have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, PRMD has a market cap of 5610.00. Regarding current trading prices, RVLWF is priced at $0.04, while PRMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas PRMD's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, RVLWF is less volatile compared to PRMD. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MSGP has a market cap of 5191.00. Regarding current trading prices, RVLWF is priced at $0.04, while MSGP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MSGP's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, RVLWF and MSGP have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MSITF has a market cap of 4800.00. Regarding current trading prices, RVLWF is priced at $0.04, while MSITF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MSITF's P/E ratio is -0.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to MSITF's ROE of N/A. Regarding short-term risk, RVLWF and MSITF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ERUC has a market cap of 3915.00. Regarding current trading prices, RVLWF is priced at $0.04, while ERUC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ERUC's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to ERUC's ROE of N/A. Regarding short-term risk, RVLWF is less volatile compared to ERUC. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SLHPF has a market cap of 3901.00. Regarding current trading prices, RVLWF is priced at $0.04, while SLHPF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SLHPF's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to SLHPF's ROE of +0.00%. Regarding short-term risk, RVLWF is less volatile compared to SLHPF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, WEQL has a market cap of 3534.00. Regarding current trading prices, RVLWF is priced at $0.04, while WEQL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas WEQL's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to WEQL's ROE of N/A. Regarding short-term risk, RVLWF and WEQL have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BBAL has a market cap of 3354.00. Regarding current trading prices, RVLWF is priced at $0.04, while BBAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BBAL's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to BBAL's ROE of N/A. Regarding short-term risk, RVLWF and BBAL have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, PAOG has a market cap of 2478.00. Regarding current trading prices, RVLWF is priced at $0.04, while PAOG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas PAOG's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to PAOG's ROE of +0.08%. Regarding short-term risk, RVLWF is less volatile compared to PAOG. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NMMCF has a market cap of 2087.00. Regarding current trading prices, RVLWF is priced at $0.04, while NMMCF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NMMCF's P/E ratio is 0.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to NMMCF's ROE of +0.00%. Regarding short-term risk, RVLWF is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, PPRG has a market cap of 1580.00. Regarding current trading prices, RVLWF is priced at $0.04, while PPRG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas PPRG's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to PPRG's ROE of N/A. Regarding short-term risk, RVLWF and PPRG have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NIVFW has a market cap of 1571.00. Regarding current trading prices, RVLWF is priced at $0.04, while NIVFW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NIVFW's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to NIVFW's ROE of -0.39%. Regarding short-term risk, RVLWF is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, OHAQ has a market cap of 1375.00. Regarding current trading prices, RVLWF is priced at $0.04, while OHAQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, RVLWF's ROE is +3.95%, compared to OHAQ's ROE of N/A. Regarding short-term risk, RVLWF and OHAQ have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BNKL has a market cap of 1248.00. Regarding current trading prices, RVLWF is priced at $0.04, while BNKL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BNKL's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, RVLWF and BNKL have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, MAHN has a market cap of 1211.00. Regarding current trading prices, RVLWF is priced at $0.04, while MAHN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas MAHN's P/E ratio is 0.05. In terms of profitability, RVLWF's ROE is +3.95%, compared to MAHN's ROE of N/A. Regarding short-term risk, RVLWF is less volatile compared to MAHN. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SLHGF has a market cap of 398.00. Regarding current trading prices, RVLWF is priced at $0.04, while SLHGF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SLHGF's P/E ratio is -0.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to SLHGF's ROE of +0.00%. Regarding short-term risk, RVLWF and SLHGF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, LHRP has a market cap of 340.00. Regarding current trading prices, RVLWF is priced at $0.04, while LHRP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas LHRP's P/E ratio is 0.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to LHRP's ROE of N/A. Regarding short-term risk, RVLWF and LHRP have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, IONM has a market cap of 313.00. Regarding current trading prices, RVLWF is priced at $0.04, while IONM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas IONM's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to IONM's ROE of +0.75%. Regarding short-term risk, RVLWF is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NMSCA has a market cap of 275.00. Regarding current trading prices, RVLWF is priced at $0.04, while NMSCA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NMSCA's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to NMSCA's ROE of N/A. Regarding short-term risk, RVLWF and NMSCA have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, INDR has a market cap of 132.00. Regarding current trading prices, RVLWF is priced at $0.04, while INDR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas INDR's P/E ratio is -0.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to INDR's ROE of N/A. Regarding short-term risk, RVLWF and INDR have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NRTSF has a market cap of 78.00. Regarding current trading prices, RVLWF is priced at $0.04, while NRTSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NRTSF's P/E ratio is 0.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to NRTSF's ROE of +0.00%. Regarding short-term risk, RVLWF and NRTSF have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SDNI has a market cap of 18.00. Regarding current trading prices, RVLWF is priced at $0.04, while SDNI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SDNI's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to SDNI's ROE of N/A. Regarding short-term risk, RVLWF and SDNI have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, ROIX has a market cap of 12.00. Regarding current trading prices, RVLWF is priced at $0.04, while ROIX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas ROIX's P/E ratio is -0.00. In terms of profitability, RVLWF's ROE is +3.95%, compared to ROIX's ROE of N/A. Regarding short-term risk, RVLWF and ROIX have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, HNGR comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while HNGR trades at $18.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas HNGR's P/E ratio is 19.71. In terms of profitability, RVLWF's ROE is +3.95%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, RVLWF is less volatile compared to HNGR. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SLHG comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while SLHG trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SLHG's P/E ratio is -1.48. In terms of profitability, RVLWF's ROE is +3.95%, compared to SLHG's ROE of N/A. Regarding short-term risk, RVLWF is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BDYS comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while BDYS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BDYS's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to BDYS's ROE of N/A. Regarding short-term risk, RVLWF is less volatile compared to BDYS. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, NFH comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while NFH trades at $11.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas NFH's P/E ratio is -19.75. In terms of profitability, RVLWF's ROE is +3.95%, compared to NFH's ROE of -0.06%. Regarding short-term risk, RVLWF is less volatile compared to NFH. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TLMDW comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while TLMDW trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TLMDW's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, RVLWF is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, BKDTU comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while BKDTU trades at $50.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas BKDTU's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to BKDTU's ROE of N/A. Regarding short-term risk, RVLWF and BKDTU have similar daily volatility (0.00).

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, DVCR comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while DVCR trades at $10.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas DVCR's P/E ratio is 28.34. In terms of profitability, RVLWF's ROE is +3.95%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, RVLWF is less volatile compared to DVCR. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, DCGOW comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while DCGOW trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas DCGOW's P/E ratio is N/A. In terms of profitability, RVLWF's ROE is +3.95%, compared to DCGOW's ROE of +0.00%. Regarding short-term risk, RVLWF is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TVTY comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while TVTY trades at $32.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TVTY's P/E ratio is 19.06. In terms of profitability, RVLWF's ROE is +3.95%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, RVLWF is less volatile compared to TVTY. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, TLMD comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while TLMD trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas TLMD's P/E ratio is -1.60. In terms of profitability, RVLWF's ROE is +3.95%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, RVLWF is less volatile compared to TLMD. This indicates potentially lower risk in terms of short-term price fluctuations for RVLWF.

RVLWF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RVLWF stands at 38.58B. In comparison, SLHGP comparison data is unavailable. Regarding current trading prices, RVLWF is priced at $0.04, while SLHGP trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RVLWF currently has a P/E ratio of -0.30, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, RVLWF's ROE is +3.95%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, RVLWF and SLHGP have similar daily volatility (0.00).